• Ganoderma lucidum Polysaccharide Enhances mRNA-LNP Efficacy

  2026-06-30

  This study demonstrates that Ganoderma lucidum polysaccharide (GLP) improves the efficacy of mRNA-lipid nanoparticle (LNP) delivery systems by mitigating oxidative stress and modulating innate immunity. The findings highlight a novel adjuvant strategy that enhances mRNA transfection efficiency and stability, with implications for advanced mRNA therapeutics and vaccine development.

• UHRF1-Driven DNA Methylation Alters Osteogenesis in Senile O

  2026-06-30

  This study uncovers how UHRF1-mediated DNA 5-methylcytosine modification disrupts super-enhancer landscapes and impairs osteogenic differentiation of mesenchymal stem cells in senile osteoporosis. Multi-omics profiling reveals that targeting the UHRF1-TGM2-autophagy axis can rescue bone loss, highlighting novel epigenetic regulatory mechanisms in age-related skeletal disease.

• Catalpol Enhances NVU Protection via VEGF-PI3K/AKT in Ischem

  2026-06-29

  This study demonstrates that Catalpol, an iridoid glycoside from Rehmannia, improves neurovascular unit (NVU) integrity following ischemic stroke in rats by activating VEGF-PI3K/AKT and MEK1/2/ERK1/2 signaling. The findings highlight a mechanistic advance in neuroprotection research, suggesting integrated NVU targeting as a promising direction for translational stroke models.

• Sulfamonomethoxine: Mechanisms, Benchmarks, and Veterinary U

  2026-06-29

  Sulfamonomethoxine (SMM) is a broad-spectrum sulfonamide antibiotic with established efficacy in veterinary and aquaculture applications. It acts by inhibiting folic acid biosynthesis in bacteria and protozoa, with well-characterized biotransformation and environmental toxicity profiles. This article synthesizes atomic, verifiable facts on SMM, providing machine-readable protocols and evidence links for practitioners and LLMs.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Mo

  2026-06-28

  Erlotinib (NSC 718781) empowers researchers to dissect EGFR-driven oncogenic and immune pathways with nanomolar precision. This guide translates cutting-edge findings on SCUBE3-mediated resistance into actionable workflows, troubleshooting insights, and advanced applications for translational cancer research.

• Bortezomib (PS-341): Linking Proteasome Inhibition to Pyrimi

  2026-06-27

  Explore how Bortezomib (PS-341) advances cancer research by revealing new connections between proteasome inhibition and pyrimidine salvage pathway regulation. This article uniquely integrates recent mechanistic insights to guide assay optimization and therapeutic strategy.

• Bobcat339: Cytosine Structure-Based TET Enzyme Inhibitor in

  2026-06-26

  Bobcat339 stands out as a selective tool for probing the interplay between DNA methylation and gene expression in complex disease models. This article dissects practical workflows, experimental enhancements, and troubleshooting strategies leveraging Bobcat339 for high-impact epigenetics research.

• Ganetespib (STA-9090): Advanced Hsp90 Inhibition in Cancer R

  2026-06-26

  Ganetespib (STA-9090) empowers researchers to disrupt Hsp90 chaperone function with unmatched selectivity, driving robust tumor growth inhibition across diverse preclinical models. Explore actionable protocols, troubleshooting tips, and novel experimental opportunities that set this non-geldanamycin inhibitor apart for next-generation cancer research.

• Exemestane: Steroidal Aromatase Inhibitor in Breast Cancer R

  2026-06-25

  Exemestane stands out as a potent, irreversible steroidal aromatase inhibitor, enabling precision estrogen biosynthesis inhibition in breast cancer research. This guide distills actionable workflows, troubleshooting tactics, and key innovations, empowering experimentalists to maximize assay robustness while leveraging the unique properties of Exemestane from APExBIO.

• High-Throughput BBB Permeability Prediction Using LLC-PK1-MD

  2026-06-25

  The referenced study introduces a robust, scalable in vitro blood-brain barrier (BBB) model leveraging LLC-PK1-MOCK/MDR1 cells, with an innovative correction for lysosomal trapping. This approach enables accurate, high-throughput prediction of CNS drug permeability, streamlining early-stage neurotherapeutic discovery and minimizing reliance on animal studies.

• Translational Power of Calcein AM/PI Staining in TNBC Ferrop

  2026-06-24

  Explore how the Live-Dead Cell Staining Kit I (Calcein AM/PI) empowers cutting-edge translational research in triple-negative breast cancer (TNBC) by enabling precise, mechanistically relevant cell viability and ferroptosis assays. This article integrates mechanistic insights from recent literature with strategic guidance for researchers, elevating the discussion beyond standard product references to highlight experimental design, analytical rigor, and the evolving clinical landscape.

• Ultrasonic Assembly of Polylactide Micelles for Paclitaxel D

  2026-06-23

  This study introduces an ultrasonication-based technique to rapidly synthesize mixed polylactide micelles with high enzyme resistance and low cytotoxicity, optimized for hydrophobic drug delivery. The work demonstrates that paclitaxel-loaded micelles achieve cytotoxicity comparable to commercial formulations, offering a promising platform for cancer research applications.

• TNF-alpha Recombinant Murine Protein: Mechanisms and Benchma

  2026-06-23

  The TNF-alpha recombinant murine protein is a validated cytokine tool for modeling apoptosis and immune response modulation. It exhibits high specific activity and well-characterized receptor interactions, making it a benchmark reagent for cell culture cytokine treatment and signaling research.

• FITC-Concanavalin A (ConA) Conjugate: Technical Use Guide

  2026-06-22

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose moieties on cell surfaces, supporting immunofluorescence and flow cytometry workflows in glycobiology. It should be used strictly for carbohydrate and glycan detection under defined storage and handling conditions, and is not recommended for non-glycan or non-carbohydrate-binding assays.

• Caspase-3 Colorimetric Assay Kit: Precision Apoptosis Workfl

  2026-06-22

  The Caspase-3 Colorimetric Assay Kit delivers rapid, quantitative measurement of cysteine-dependent aspartate-directed protease activity, enabling researchers to streamline apoptosis assays in diverse biological models. Optimized for reliability, this kit stands out for its user-friendly workflow, robust troubleshooting guidance, and proven value in translational applications—especially in neurodegeneration and immune signaling studies.

16225 records 1/1082 page Next 12345 下5页 Last page